Nothing Special   »   [go: up one dir, main page]

HUE051674T2 - Eszközök és eljárások rákos beteg kezelésére adott válaszának elõrejelzésére - Google Patents

Eszközök és eljárások rákos beteg kezelésére adott válaszának elõrejelzésére

Info

Publication number
HUE051674T2
HUE051674T2 HUE11773381A HUE11773381A HUE051674T2 HU E051674 T2 HUE051674 T2 HU E051674T2 HU E11773381 A HUE11773381 A HU E11773381A HU E11773381 A HUE11773381 A HU E11773381A HU E051674 T2 HUE051674 T2 HU E051674T2
Authority
HU
Hungary
Prior art keywords
prediction
methods
cancer patient
treatment response
response
Prior art date
Application number
HUE11773381A
Other languages
English (en)
Inventor
Niels Grabe
Dirk JÄGER
Niels Halama
Inka Zoernig
Original Assignee
Niels Grabe
Jaeger Dirk
Halama Niels Dr
Inka Zoernig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44862915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE051674(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Niels Grabe, Jaeger Dirk, Halama Niels Dr, Inka Zoernig filed Critical Niels Grabe
Publication of HUE051674T2 publication Critical patent/HUE051674T2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96436—Granzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
HUE11773381A 2010-09-24 2011-09-20 Eszközök és eljárások rákos beteg kezelésére adott válaszának elõrejelzésére HUE051674T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10010537 2010-09-24

Publications (1)

Publication Number Publication Date
HUE051674T2 true HUE051674T2 (hu) 2021-03-29

Family

ID=44862915

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11773381A HUE051674T2 (hu) 2010-09-24 2011-09-20 Eszközök és eljárások rákos beteg kezelésére adott válaszának elõrejelzésére

Country Status (10)

Country Link
US (1) US9726676B2 (hu)
EP (1) EP2619576B1 (hu)
DK (1) DK2619576T3 (hu)
ES (1) ES2816625T3 (hu)
HR (1) HRP20201424T1 (hu)
HU (1) HUE051674T2 (hu)
PL (1) PL2619576T3 (hu)
PT (1) PT2619576T (hu)
SI (1) SI2619576T1 (hu)
WO (1) WO2012038068A2 (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
US20120171694A1 (en) * 2010-07-30 2012-07-05 Vermillion, Inc. Predictive markers and biomarker panels for ovarian cancer
RU2626540C2 (ru) 2011-04-18 2017-07-28 Диамир, Ллс Способы обнаружения патологических изменений в органе или системе органов
US9760760B2 (en) * 2012-01-19 2017-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histology recognition to automatically score and quantify cancer grades and individual user digital whole histological imaging device
US20130203614A1 (en) * 2012-02-08 2013-08-08 Jerome Galon Methods for predicting the survival time of a patient suffering from a solid cancer
CA2868159A1 (en) * 2012-03-30 2013-10-03 Sloan-Kettering Institute For Cancer Research S100a8/a9 as a diagnostic marker and a therapeutic target
ES2702722T3 (es) * 2012-08-06 2019-03-05 Inst Nat Sante Rech Med Métodos y kits para cribar pacientes con cáncer
JP6277190B2 (ja) * 2012-08-21 2018-02-07 メディテクト アーベー 改善された細胞の同定のための方法
US20150250826A1 (en) * 2012-09-06 2015-09-10 Joslin Diabetes Center, Inc. Isolation and characterization of muscle regenerating cells
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014173860A1 (en) * 2013-04-23 2014-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a combination of iron uptake inhibitor and vitamin d receptor agonist
CN105917005B (zh) 2013-11-18 2020-09-11 迪阿米尔有限责任公司 使用来自体液的miRNA检测和监控帕金森病(PD)的方法
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
AU2015220783B2 (en) * 2014-02-24 2021-02-04 Ventana Medical Systems, Inc. Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of CD3, CD8, CD20, and FoxP3
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
KR101751929B1 (ko) * 2015-01-05 2017-06-28 서울대학교 산학협력단 신규 간암 환자의 소라페닙 저항성 예측 마커
US20160258848A1 (en) * 2015-03-04 2016-09-08 Agilent Technologies, Inc. Methods and compositions for multiplex tissue section analyses using visible and non-visible labels
EP3839510A3 (en) * 2015-04-17 2021-08-25 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
KR20170007181A (ko) 2015-07-10 2017-01-18 3스캔 인크. 조직학적 염색제의 공간 다중화
ES2955775T3 (es) 2015-08-27 2023-12-07 Inst Nat Sante Rech Med Métodos para predecir el tiempo de supervivencia de pacientes que padecen cáncer de pulmón
JP6898316B2 (ja) * 2015-10-23 2021-07-07 ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ 拡張版ａｑｕａを支援するコンピュータ処理
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
EP3433381B1 (en) 2016-03-21 2024-07-24 Diamir, LLC Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
WO2017189526A1 (en) * 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
CN106084114B (zh) * 2016-06-08 2017-11-10 渤海大学 一种恩诺沙星适配体/分子印迹杂化型上转换荧光探针的制备方法
US9990713B2 (en) * 2016-06-09 2018-06-05 Definiens Ag Detecting and visualizing correlations between measured correlation values and correlation reference values of a pathway
BR112019003248A2 (pt) * 2016-08-19 2019-10-01 Brooklyn Immunotherapeutics Llc usos de inibidores de pd-1/pd-l1 e/ou inibidores de ctla-4 com um biológico contendo múltiplos componentes citocínicos para o tratamento de câncer
EP3515495A4 (en) * 2016-09-26 2020-08-26 Ensemble Group Holdings METHOD OF EVALUATION AND TREATMENT OF CANCER IN HUMANS WITH DYSREGULATED LYMPHATIC SYSTEMS
WO2018102567A1 (en) * 2016-12-01 2018-06-07 Yale University Prediction of response to immune-modulatory therapies
WO2018209324A2 (en) * 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2018231772A1 (en) * 2017-06-13 2018-12-20 Bostongene Corporation Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
KR20200026286A (ko) * 2017-07-05 2020-03-10 더 리전트 오브 더 유니버시티 오브 캘리포니아 장기 기능 복구의 수술전 예측을 위한 검정
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
US10950424B2 (en) * 2017-09-25 2021-03-16 Bruker Daltonik, Gmbh Method for monitoring the quality of mass spectrometric imaging preparation workflows
JP7355294B2 (ja) * 2017-11-30 2023-10-03 シンガポール ヘルス サービシズ ピーティーイー． リミテッド がん患者を適切ながん処置群に分類するためのシステム及び方法、並びに患者を処置するための化合物
EP3887548A1 (en) * 2018-11-30 2021-10-06 GBG Forschungs GmbH Method for predicting the response to cancer immunotherapy in cancer patients
CN109655624A (zh) * 2019-02-11 2019-04-19 臻和（北京）科技有限公司 一种用于预测癌症免疫治疗效果的标志物及其应用、试剂盒和试剂盒的制备方法
AU2020288603A1 (en) 2019-06-03 2021-12-16 Assistance Publique - Hôpitaux De Paris Methods for modulating a treatment regimen
US20220357329A1 (en) * 2019-07-01 2022-11-10 Accure Health Inc. Predictive liquid markers for cancer immunotherapy
CN110895280B (zh) * 2019-12-03 2022-11-18 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌转移的免疫评分及其应用
WO2021156360A1 (en) * 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
EP4100962A1 (en) * 2020-02-07 2022-12-14 Sanofi Systems and methods for predicting patient responses
US20210277345A1 (en) * 2020-03-06 2021-09-09 Tomoyuki Aratani Cell-containing container, method for evaluating test substance, and method for manufacturing cell-containing container
EP4321625A1 (en) * 2021-04-06 2024-02-14 Industry Foundation of Chonnam National University Method for predicting prognosis and responsiveness to anticancer therapy of cancer patients
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统
CN114622023A (zh) * 2021-09-09 2022-06-14 四川省肿瘤医院 一种预测肿瘤化疗联合免疫治疗疗效的标志物及其应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
WO2024215562A1 (en) * 2023-04-13 2024-10-17 Board Of Regents, The University Of Texas System Pre-treatment prediction of the response of cancer to neoadjuvant therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6711283B1 (en) * 2000-05-03 2004-03-23 Aperio Technologies, Inc. Fully automatic rapid microscope slide scanner
US7596249B2 (en) * 2002-02-22 2009-09-29 Olympus America Inc. Focusable virtual microscopy apparatus and method
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
GB0601509D0 (en) * 2006-01-26 2006-03-08 Maddison John Method And Apparatus For Aligning Microscope Images

Also Published As

Publication number Publication date
WO2012038068A2 (en) 2012-03-29
PL2619576T3 (pl) 2021-07-05
DK2619576T3 (da) 2020-09-07
PT2619576T (pt) 2020-09-14
WO2012038068A3 (en) 2012-05-31
EP2619576B1 (en) 2020-06-10
US20130330325A1 (en) 2013-12-12
EP2619576A2 (en) 2013-07-31
US9726676B2 (en) 2017-08-08
WO2012038068A8 (en) 2013-11-28
ES2816625T3 (es) 2021-04-05
HRP20201424T1 (hr) 2021-02-19
SI2619576T1 (sl) 2021-03-31

Similar Documents

Publication Publication Date Title
PT2619576T (pt) Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
IL261768B (en) Devices and methods for tissue treatment
ZA201209484B (en) Skin antiaging treatment
EP2611496A4 (en) Methods of Treatment
ZA201300218B (en) Treatment of blood cancer
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
SG10201508495VA (en) Combination treatment of cancer
ZA201301601B (en) Treatment of diseases
EP2613786A4 (en) TREATMENT OF DISEASES
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
IL222958A0 (en) Cancer treatment
GB201005662D0 (en) Phototherapeutic treatment of acne
ZA201300762B (en) Novel combination therapy for the treatment of cancer
IL256026B (en) Treatment methods
EP2635121A4 (en) ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
IL275636A (en) Medical combination for cancer treatment
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
EP2556161A4 (en) METHODS OF TREATING AUTOIMMUNE DISEASES
EP2585115A4 (en) CANCER THERAPY
GB201016864D0 (en) Therapeutic methods
PL2566579T3 (pl) Urządzenie medyczne do magnetoterapii
GB201113140D0 (en) Prediction and treatment of cancer
IL204097A0 (en) Medicine for the treatment of skin cancer
GB2477546B (en) Skin treatment apparatus